Literature DB >> 12032833

Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain.

Akhilesh Pandey1, Ippeita Dan, Troels Z Kristiansen, Norinobu M Watanabe, Jesper Voldby, Eriko Kajikawa, Roya Khosravi-Far, Blagoy Blagoev, Matthias Mann.   

Abstract

The p21-activated kinase (PAK) family of protein kinases has recently attracted considerable attention as an effector of Rho family of small G proteins and as an upstream regulator of MAPK signalling pathways during cellular events such as re-arrangement of the cytoskeleton and apoptosis. We have cloned a novel human PAK family kinase that has been designated as PAK5. PAK5 contains a CDC42/Rac1 interactive binding (CRIB) motif at the N-terminus and a Ste20-like kinase domain at the C-terminus. PAK5 is structurally most related to PAK4 and PAK6 to make up the PAK-II subfamily. We have shown that PAK5 preferentially binds to CDC42 in the presence of GTP and that CRIB motif is essential for this interaction. PAK5 is a functional protein kinase but unlike PAK-I family kinases (PAK1, 2, and 3), the kinase activity of PAK5 does not seem to require the binding of CDC42. Overexpression of PAK5 activates the JNK kinase pathway but not p38 or ERK pathways. PAK5 transcript is predominantly expressed in brain as revealed by Northern blot and in situ hybridization. The expression pattern of PAK5 is distinct from that of PAK4 and PAK6, suggesting a functional division among PAK-II subfamily kinases based on differential tissue distribution.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032833     DOI: 10.1038/sj.onc.1205478

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

1.  Targeted disruption of the gene for the PAK5 kinase in mice.

Authors:  Xiaofan Li; Audrey Minden
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

Review 2.  PAK and other Rho-associated kinases--effectors with surprisingly diverse mechanisms of regulation.

Authors:  Zhou-shen Zhao; Ed Manser
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

Review 3.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

4.  PAK6 targets to cell-cell adhesions through its N-terminus in a Cdc42-dependent manner to drive epithelial colony escape.

Authors:  Elizabeth M Morse; Xiaowen Sun; Jordan R Olberding; Byung Hak Ha; Titus J Boggon; David A Calderwood
Journal:  J Cell Sci       Date:  2015-11-23       Impact factor: 5.285

Review 5.  Signaling, Regulation, and Specificity of the Type II p21-activated Kinases.

Authors:  Byung Hak Ha; Elizabeth M Morse; Benjamin E Turk; Titus J Boggon
Journal:  J Biol Chem       Date:  2015-04-08       Impact factor: 5.157

6.  PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin.

Authors:  Dorthe Matenia; Bettina Griesshaber; Xiao-yu Li; Anja Thiessen; Cindy Johne; Jian Jiao; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  Mol Biol Cell       Date:  2005-07-12       Impact factor: 4.138

Review 7.  P21 activated kinases: structure, regulation, and functions.

Authors:  Chetan K Rane; Audrey Minden
Journal:  Small GTPases       Date:  2014-03-21

8.  Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic properties.

Authors:  Sophie Cotteret; Jonathan Chernoff
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

9.  Differential sensitivity of Pak5, Pak6, and Pak5/Pak6 double-knockout mice to the stimulant effects of amphetamine and exercise-induced alterations in body weight.

Authors:  Melody A Furnari; Michelle L Jobes; Tanya Nekrasova; Audrey Minden; George C Wagner
Journal:  Nutr Neurosci       Date:  2013-11-26       Impact factor: 4.994

Review 10.  PAK signaling in oncogenesis.

Authors:  P R Molli; D Q Li; B W Murray; S K Rayala; R Kumar
Journal:  Oncogene       Date:  2009-05-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.